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Stent dislodgment is one catastrophic complication of percutaneous coronary 
intervention (PCI), especially in tortuous and calcified lesions. The anti-dislodgment 
capability of different stent platforms may be varied due to different designs. 
However, data on the anti-dislodgment capability of contemporary stent platforms are 
still unavailable. Thus, the aim herein, was to compare the anti-dislodgment capability 
of different stent platforms with a bench test. 
Three types of stent platforms (n = 3 for each stent platform) were included in 
the bench test, including XIENCE Xpedition (3.0 × 23 mm, Abbott), Resolute 
Integrity (3.0 × 22 mm, Medtronic), Synergy (3.0 × 24 mm, Boston Scientific). The 
anti-dislodgment capability was assessed by Instron 5943 (Boston, US). Appropriate 
stent holder was determined according to the profile measurement of each stent (Inner 
diameter of stent holder = measured stent profile – 2 × structs thickness). The force 
was recorded during the pullback process with the speed of 50.8 mm/min. Maximal 
dislodgement force was defined as the first peak value of the force record in 5 mm 
pullback. Operators were blinded to the brands of the stent platforms. Study design 
was in accordance with two standard guides from China (standard guide for 
measuring securement of balloon expandable vascular stent mounted on delivery 
system, YY/T 0807-2010, 
https://www.chinesestandard.net/China/Chinese.aspx/YYT0807-2010; Cardiovascular 
implants Endovascular devices. Part 2: Vascular stents, YY/T 0663.2-2016, 
https://www.chinesestandard.net/China/Chinese.aspx/YYT0663.2-2016). Data were 
presented as median [interquartile range]. Group comparisons were performed using 
the Kruskal-Wallis test with a post-hoc test. All statistical tests were performed using 
GraphPad Prism version 5.00 (GraphPad Software, San Diego California USA) in a 
two-sided manner. Values of p < 0.05 were considered statistically significant.  
The recorded force of each stent during the pullback process was presented in 
Figure 1A–C. The median of maximal dislodgement force for 3 stent platforms was as 
follows: XIENCE Xpedition group: 10.31N; Resolute Integrity group: 6.93 N; 
Synergy group: 6.19 N. There were significant differences among the three groups (p 
= 0.027). Group comparisons indicated that XIENCE Xpedition had higher maximal 
dislodgement forces than the Synergy group (10.31 [9.76–10.33] N vs. 6.19 
[5.48-–6.50] N, p = 0.022), while there was no difference between the Resolute 
Integrity and Synergy groups (6.93 [6.64–7.00] N vs. 6.19 [5.48–6.50] N, p = 0.539), 
or between Resolute Integrity and XIENCE Xpedition (6.93 [6.64–7.00] N vs. 10.31 
[9.76–10.33] N, p = 0.539) (Fig. 1D). 
Stent dislodgment is an uncommon complication during PCI which is 
primarily due to calcification and tortuosity of the lesion. The prevalence of stent 
dislodgement was up to ~8% in the early 1990s [1]. Fortunately, the rate of stent 
dislodgement has significantly decreased which may be explained by the increased 
operator experience and advancement in stent technology [2]. Several parameters of 
stent platform including profile, flexibility, and adhesion are associated with risk of 
stent dislodgment. Data on the profiles of commercial stents are available and some 
studies have provided a numerical approach to assess the stent flexibility [3]. 
However, so far there are no published data evaluating the adhesion of stent platforms. 
The present study is the first study to assess stent adhesion with numerical data, which 
is one of the major components of anti-dislodgment capability. There are some 
potential explanations for the difference in maximal dislodgment force among three 
types of drug eluting stents (DES). First, stent platforms vary among different DES. 
XIENCE Xpedition and Resolute integrity stents use a cobalt chromium platform with 
MULTI-LINK and continuous sinusoid designs, respectively. On the other hand, 
Synergy uses the platinum chromium platform with a different number of connectors 
(e.g. 4 connectors on proximal end and 2 connectors throughout body for 2.50–3.50 
mm stents). Second, the stent crimping technique is a key determinant for maximal 
dislodgment force. However, stent crimping techniques for different DES are patented 
and are not available to the public. The current study has several limitations. First, the 
sample size was small. Second, an in-vitro study could not provide the same 
environment as in the coronary arteries. Finally, the latest generation of DES such as 
XIENCE Sierra or Resolute Onyx were not used. 
Current bench test found that anti-dislodgment capability varied among the 
stent platforms and XIENCE Xpedition may be higher than Resolute Integrity and 
Synergy. Further study is needed to verify this preliminary result. 
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Figure 1. The values of force (N) during the pullback process for different drug 
eluting stents (with the speed of 50.8 mm/min). The force curves recorded in 5 mm 
pullback for XIENCE Xpedition (A), Resolute Integrity (B), and Synergy (C); D. 
Comparison of maximal dislodgement force among three drug eluting stents. 

